Merck: Europe approves hard-to-treat liver cancer drug
(CercleFinance.com) - US biopharma giant Merck and Japanese partner Eisai said Europe has approved Lenvima as first-line treatment for advanced or unresectable hepatocellular carcinoma, a form of liver cancer for which prognosis is poor and which has limited treatment options.
Last week, both companies were already granted an approval by the US Food and Drug Administration, based on a phase 3 study in which Lenvima demonstrated a proven effect on the overall survival.
Liver cancer is the second leading cause of cancer-related deaths and is estimated to be responsible for nearly 750,000 deaths per year globally, including 69,000 per year in Europe.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Last week, both companies were already granted an approval by the US Food and Drug Administration, based on a phase 3 study in which Lenvima demonstrated a proven effect on the overall survival.
Liver cancer is the second leading cause of cancer-related deaths and is estimated to be responsible for nearly 750,000 deaths per year globally, including 69,000 per year in Europe.
Copyright (c) 2018 CercleFinance.com. All rights reserved.